On May 24, the China-British Pharmaceutical Regulatory Cooperation Dialogue was jointly organized by CCCMHPIE, the British Medicines and Healthcare products Regulatory Agency (MHRA) and UK Trade & Investment (UKTI) in Beijing. The Dialogue was in an effort to promote bilateral exchange on pharmaceutical regulatory cooperation, TCM legislation, as well as to facilitate the development of bilateral trade in medicines.
An important annual event organized by Sino-British Economic and Trade Joint Committee Pharmaceutical Medicine Technology Cooperation Working Group, the conference was co-hosted by Ni Rulin, President of CCCMHPIE and Professor Kent Woods, Chief Executive of MHRA. 35 representatives from MHRA, British Embassy in China, United Nations Industrial Development Organization, and 15 pharmaceutical enterprises attended the conference, including Lizhan Group, Beijing Tong Ren Tang Group Co., Ltd., Beijing Second Pharmaceutical Co., Ltd., Beijing Yuekang Medicine Industry Group Co., Ltd., Beijing Zizhu Pharmaceutical Co., Ltd., Beijing Pharmaceutical Group Co., Ltd., Tianjin Tasly Group, and Shandong Luye Pharmaceutical Co., Ltd.
Issues discussed at the conference included pharmaceutical registration and regulatory policy in UK and EU, TCM legislation in Britain, co-authorship on pharmaceutical monographs, British specifications on pharmaceutical production and quality control, China-British pharmaceutical cooperation and innovation, and etc.
